Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC

AstraZeneca

Status: Completed

Conditions: T790M Positive NSCLC Patients

Treatments: Drug: osimertinib

Study type: Observational

Funder types: Industry

Identifiers

NCT03133234

D5160R00016

Details and patient eligibility

About

To assess the effectiveness and safety of osimertinib treatment in a real world setting.

Full description

The current study will not only assess the effectiveness of osimertinib treatment in a real world setting, but will also help us to understand the real-world testing patterns among T790M mutation positive locally advanced or metastatic NSCLC patients who have progressed after EGFR TKI treatment.

Enrollment: 47 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Above 18 years of age;
• Locally advanced (stage IIIB) or metastatic (stage IV) NSCLC, not amenable to curative surgery or radiotherapy
• Confirmed T790M mutation
• Progressed on previous EGFR TKI treatment. Patients may have also received additional lines of treatment
• Received osimertinib treatment in the participating site between May 1st and Oct 31st 2016

Exclusion criteria

• Enrolment in studies that prohibit any participation in this observational study

Trial design

47 participants in 1 patient group

EGFR T790M Patients

Description:

Patients with locally advanced/metastatic EGFR T790M positive NSCLC progressed on previous EGFR TKI

Treatment:

Drug: osimertinib